Intech Investment Management LLC Invests $1.06 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Intech Investment Management LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 57,774 shares of the company’s stock, valued at approximately $1,064,000.

Several other institutional investors have also recently bought and sold shares of HIMS. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after buying an additional 136,907 shares during the period. Price T Rowe Associates Inc. MD increased its position in Hims & Hers Health by 239.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock worth $2,606,000 after purchasing an additional 118,848 shares during the period. Strategic Wealth Partners Ltd. bought a new stake in Hims & Hers Health during the 1st quarter worth about $839,000. Virtu Financial LLC acquired a new position in Hims & Hers Health during the 1st quarter valued at about $638,000. Finally, Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Piper Sandler restated a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $20.71.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares in the company, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anja Manuel bought 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at $107,760. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 1,153,519 shares of company stock valued at $24,486,721 in the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Trading Down 1.1 %

HIMS opened at $30.35 on Thursday. The stock has a market capitalization of $6.63 billion, a P/E ratio of 68.98 and a beta of 1.06. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The firm’s fifty day simple moving average is $21.14 and its 200 day simple moving average is $19.57.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the firm earned ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.